title: Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
abstract: Peroxisome proliferator-activator receptors (PPARs) are now known as members of the nuclear hormonereceptor superfamily of ligand-activated transcription factors that regulate gene expression in response to nutritional and physiological stimuli. PPARγ plays a crucial role in glucose homeostasis and it is involved in the regulation of lipid metabolism and adipocyte differentiation and function. From all the PAARγ ligands, the thiazolidindiones (TZDs) are of most clinical importance. Rosiglitazone and pioglitazone have been largely used so far in the clinical practice. They provide similar effects on glycemic control, as well as a range of similar adverse effects, such as weight gain, fluid retention, and increased risk of hearth failure, which seem to be PPARγ mediated. Interestingly, they differ on their effect on lipid and cardiovascular safety profile, indicating a PPARγ-independent mechanism. Indeed, rosiglitazone was recently withdrawn in Europe and its use has been restricted in USA as a consequence of increased risk of cardiovascular events in type 2 diabetic patients. This review is focused on the cardiovascular effects of rosiglitazone and pioglitazone as representative members of PPARγ ligands, because they were widely evaluated in many clinical trials and experimental studies and data obtained from these studies are relevant from medicinal chemistry and clinical pharmacology point of view. Finally, an overview on the development of selective PPARγ modulators and/or dual PPARα/γ agonists will be given. These new approaches might provide anti-hyperglycemic efficacy without the associated undesirable side-effects. However, further experimental and clinical studies evaluating the theoretical benefit and safety of this therapeutic strategy are needed.
authors.affiliation: Diabetes and Metabolism Research Unit, CIBER de Diabetes y Enfermedades Metabólicas Asociadas-CIBERDEM, Instituto de Salud Carlos III, Vall d'Hebron Institut de Recerca-VHIR, Hospital Universitari Vall d'Hebron, UniversitatAutònoma de Barcelona, Barcelona, Spain.
authors.forename: Andreea
authors.initials: A
authors.lastname: Ciudin
authors.forename: Cristina
authors.initials: C
authors.lastname: Hernandez
authors.forename: Rafael
authors.initials: R
authors.lastname: Simó
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008024:Ligands; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013329:Structure-Activity Relationship; D045162:Thiazolidinediones / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D008024:Ligands; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone